玻璃体腔雷珠单抗、曲安奈德注射治疗对湿性老年黄斑变性患者内皮抑素及房水SDF1-α、LIF水平的影响  

Effects of intravitreal ranibizumab and triamcinolone acetonide injection on the levels of endostatin,aqueous humor SDF1-α and LIF in patients with wet age-related macular degeneration

作　　者：张云[1] 王倩[1] 陶锐 徐惠娣 陆庆 陈孝霞 刘修铎 赵婕 ZHANG Yun;WANG Qian;TAO Rui;XU Huidi;LU Qing;CHEN Xiaoxia;LIU Xiuduo;ZHAO Jie(Department of Ophthalmology,Shidong Hospital Affiliated to University of Shanghai for Science and Technol-ogy,Shanghai,China,200090)

机构地区：[1]上海理工大学附属市东医院眼科,上海200090

出　　处：《分子诊断与治疗杂志》2023年第1期85-89,共5页Journal of Molecular Diagnostics and Therapy

基　　金：上海市卫生健康委员会青年课题项目(20204Y0021)。

摘　　要：目的 探讨玻璃体腔雷珠单抗、曲安奈德注射治疗对湿性老年黄斑变性(AMD)患者内皮抑素(ES)及房水基质细胞衍生因子1-α(SDF1-α)、人白血病抑制因子(LIF)水平的影响。方法 选取2016年1月至2021年12月上海市杨浦区市东医院收治的湿性AMD患者133例作为研究对象,根据治疗方式不同将患者分为对照组64例和观察组69例,对照组给予玻璃体腔注射曲安奈德治疗,观察组给予玻璃体腔注射雷珠单抗治疗。对比两组临床疗效、视力及眼压改善情况(BCVA、CFT、眼压)、炎性因子(ES、SDF1-α、LIF)、视功能损害眼病患者生存质量量表(SQOL-DVI)及不良反应发生情况。结果 观察组(94.20%)总有效率高于对照组(81.25%),差异有统计学意义(P<0.05)。观察组治疗后BCVA高于对照组,CFT、眼压均低于对照组,差异均有统计学意义(P<0.05)。治疗后,两组ES、SDF1-α和LIF水平均有所下降,且观察组治疗后ES、SDF1-α和LIF水平均明显低于对照组,差异均有统计学意义(P<0.05)。治疗后,两组SQOL-DVI各项评分均升高,且观察组治疗后明显高于对照组,差异均有统计学意义(P<0.05)。两组不良反应总发生率比较差异无统计学意义(P>0.05)。结论 玻璃体腔雷珠单抗与曲安奈德注射治疗湿性AMD疗效相比较,前者可更有效改善眼压及视力情况,调节ES、SDF1-α和LIF水平,更值得临床进一步推广应用。Objective To investigate the effects of intravitreal ranibizumab and triamcinolone acetonide injection on the levels of endostatin(ES),Stromal Cell Derived Factor 1-α(SDF1-α)and Leukemia Inhibitory Factor(LIF)in patients with wet age-related macular degeneration(AMD). Methods 133 wet AMD patients admitted to our hospital from January 2016 to December 2021 were selected as the research subjects,and according to different treatment methods,the patients were divided into the control group of 64 cases and the observation group of 69 cases,the control group was given intravitreal injection of triamcinolone acetonide,and the observation group were given intravitreal injection of ranibizumab. The clinical efficacy,improvement of visual acuity and intraocular pressure(BCVA、CFT、Intraocular pressure),inflammatory factors(ES、SDF1-α、LIF),the Scale of Life Quality for Diseases with Visual Impairment(SQOL-DVI)and adverse reactions were compared between the two groups. Results The total effective rate in the observation group(94.20%)was higher than that in the control group(81.25%)(P<0.05). After treatment,BCVA in the observation group was higher than that in the control group,CFT and IOP were lower than those in the control group,the differences were statistically significant(P<0.05). After treatment,the levels of ES,SDF1-α and LIF in 2 groups were decreased,and the levels of ES,SDF1-α and LIF in the observation group were significantly lower than those in the control group after treatment,with statistical significance(P<0.05). After treatment,the scores of SQOL-DVI in both groups were increased,and the scores in the observation group was significantly higher than those in the control group after treatment,with statistical significance(P<0.05). There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05). Conclusion Compared with intravitreal ranibizumab and triamcinolone injection in the treatment of wet AMD,the former can improve IOP and visual acuity more effect

关 键 词：湿性老年黄斑变性 玻璃体腔雷珠单抗 曲安奈德 SDF1-α LIF 

分 类 号：R774.5[医药卫生—眼科]